CN102389533B - Medicinal composition for treating cerebral apoplexy and preparation method thereof - Google Patents
Medicinal composition for treating cerebral apoplexy and preparation method thereof Download PDFInfo
- Publication number
- CN102389533B CN102389533B CN2011103555785A CN201110355578A CN102389533B CN 102389533 B CN102389533 B CN 102389533B CN 2011103555785 A CN2011103555785 A CN 2011103555785A CN 201110355578 A CN201110355578 A CN 201110355578A CN 102389533 B CN102389533 B CN 102389533B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicinal composition
- pharmaceutical composition
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006011 Stroke Diseases 0.000 title abstract description 19
- 206010008190 Cerebrovascular accident Diseases 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 title abstract description 14
- 230000002490 cerebral effect Effects 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 54
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 19
- 206010008118 cerebral infarction Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 17
- 239000002994 raw material Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 2
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010004542 Bezoar Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 241000949648 Angulus Species 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010063900 Steal syndrome Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 238000002585 cerebral angiography Methods 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating cerebral apoplexy. The composition is prepared from the following raw materials, by weight, 35 parts of Chinese angelica, 30 parts of chrysanthemum, 25 parts of safflower, 20 parts of Radix Puerariae, 18g of mint, 18 parts of peach kernel, 16 parts of white peony root, 12 parts of antler, 12 parts of Rhizoma Cibotii, 10 parts of Salvia miltiorrhiza, 10 parts of Radix Astragali, 8 parts of Cassia Twig, 8 parts of rhizoma gastrodiae, 6 parts of Achyranthes bidentata, 6 parts of Lycium chinense, 3 parts of cinnamon and 3 parts of Radix Polygalae. After clinical verification, the medicinal composition of the invention allows twenty-five cases to be cured, is effective to twelve cases and is ineffective to two cases when thirty-nine cases is treated by the medicinal composition for 2-3 months, so the total effective rate is 95%. The medicinal composition of the invention, which has the advantages of simple preparation, simultaneous treatment of principal and subordinate symptoms, no side effect, and low price, has a wide application prospect.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of Chinese medicine composition for the treatment of apoplexy, relate in particular to a kind of pharmaceutical composition of cerebral infarction.
Background technology
Apoplexy (Stroke) is the formal name used at school of apoplexy, is a kind of cerebral blood circulation obstacle disease of unexpected onset.Be cerebrovascular accident again.The patient who refers at cerebrovascular disease, because various risk factors cause stricture of artery in the brain, inaccessible or break, and cause the acute brain disturbance of blood circulation, show as a sings and symptoms of crossing property or permanent disordered brain function clinically. apoplexy is divided in the ischemic cerebral apoplexy and hemorrhagic apoplexy.
Cerebral infarction is the cerebral infarction of broad sense, refers to that the local feeding artery blood perfusion of the cerebral tissue that takes place suddenly reduces or blood flow interrupts fully, stops blood supply, oxygen supply, supplies sugar etc., and this local brain tissue disintegrate is destroyed.The main cause of cerebral infarction is: cerebral embolism, a variety of causes cause due to the embolus in thromboembolism, heart source due to the atherosclerosis vasculitis, blood vessel injury and wound etc.Cerebral infarction is generally fallen ill in nighttime sleep, and Chang Weici WA in morning is found limb adynamia or hemiplegia, how unconscious obstacle, and blood pressure can be normal or higher, and the arteriosclerosis history can be arranged.Cerebral infarction accounts for the over half of cerebral apoplexy patient sum, mainly comprises cerebral thrombosis and cerebral embolism.
Treatment cerebral infarction main method is to improve the blood circulation of brain at present, the blood flow in half blanking bar district of increase ischemic region and the supply of oxygen, and the control cerebral edema is prevented and treated complication.Along with the application of evidence-based medicine EBM concept, both at home and abroad cerebrovascular information is sought, estimate.By the meta-analysis evaluation of circulation medical science, have only 4 kinds of therapies that Ischemic Stroke is had sure curative effect at present, that is exactly acute stroke unit, thromboembolism treatment, Antiplatelet therapy and anticoagulant therapy.The surgical intervention carotid endarterectomy is suitable for the outer section of internal carotid artery cranium seriously narrow (stenosis surpasses 50%), and narrow positions is at the following operator of angulus mandibulae and can.Inaccessible 24 hours of completeness also can be considered operation with interior, inaccessiblely surpasses 24-48 hour, and cerebral malacia person has been taken place, should not perform the operation.
The medicine of cerebral infarction has multiple, and the first kind is vasodilator.Think in the past as long as medicine can make cerebral vasodilators, blood multithread from the blood vessel that stops up is gone over.Find that but not only Pimobendane do not accomplish this point, the blood reflux of diseased region is flow in the healthy cerebral tissue go (this is called steal syndrome in the brain), so do not advocated to use this type of medicine.Second class is thrombolytic medicine, is ideal if use the purpose that this type of medicine can reach the dissolving embolus, but often needs heavy dose during the systemic vein medication, causes danger of bleeding sometimes.Present multidirectional patient recommends to use interventional therapy, by conduit embolus is dissolved at the position that medicine directly injects infarction exactly, but take the front and back of this Therapeutic Method all will do cerebral angiography one time, this itself just has certain danger again, in addition interventional therapy requires patient carrying out in 6 hours after being ill, has often missed opportunity sometimes.The 3rd class medicine is the medicine that prevents platelet aggregation, aspirin for example, and hematoblastic cohesion is the beginning of cerebral thrombosis often, if the cohesion of blocking platelet effectively, the osmanthus of perhaps preventing stopping blooding further forms.At present this class medicine is used very extensively in the world, not equal to but be to be more appropriate as prophylactic agent as medicine, because the acute stage of apoplexy, use this class effect of drugs unsatisfactory.The 4th class is Chinese medicine.The main effect of Chinese medicine is activating blood circulation to dissipate blood stasis, and application is extremely extensive at home now, and oral medicine is not only arranged, and also has intravenous injection and intramuscular injection medicine, uses easily.Some patient and family members think that the Chinese medicine cow-bezoar bolus for resurrection is apoplexy " specific drug " now; but assign to analyze from the one-tenth of cow-bezoar bolus for resurrection; medicine have bring down a fever, the relieving convulsion and effect of having one's ideas straightened out; apoplexy to unconsciousness, hyperpyrexia and convulsion is effective; and it is just not necessarily effective to other types; so can't generally be called " specific drug ", should come medication according to the determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs principle of apoplexy.
This shows, need a kind of Chinese herb medicine of effective treatment cerebral infarction in the prior art, and can not produce more serious toxic and side effects.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides pharmaceutical composition of a kind of effective treatment cerebral infarction and preparation method thereof.
The objective of the invention is in order to overcome disadvantages of background technology, and pharmaceutical composition of a kind of effective treatment cerebral infarction that provides and preparation method thereof.The present application people in conjunction with secret prescription handed down in the family from generation to generation according to forefathers' experience and oneself medical practice for many years, by the research to Chinese medicine, and in conjunction with dialectical demonstration, collect the length of many families in many ways, seek therapeutic regimen, adopt the natural Chinese medicines raw material, be mixed with the Chinese herb medicine of cerebral infarction of the present invention meticulously in conjunction with traditional lunar physics technique, its compound method is simple, can use in hospital with the medicine of said composition preparation, also can provide for oneself, need the time spent to modulate use voluntarily.
The technical problem of the desired solution of the present invention realizes by following technological approaches.
A kind of pharmaceutical composition for the treatment of cerebral infarction, it is got than feedstock production by following weight:
Radix Angelicae Sinensis 35, Flos Chrysanthemi 30, Flos Carthami 25, Radix Puerariae 20, Herba Menthae 18, Semen Persicae 18, the Radix Paeoniae Alba 16, Cornu Cervi 12, Rhizoma Cibotii 12, Radix Salviae Miltiorrhizae 10, the Radix Astragali 10, Ramulus Cinnamomi 8, Rhizoma Gastrodiae 8, Radix Achyranthis Bidentatae 6, Fructus Lycii 6, Cortex Cinnamomi 3, Radix Polygalae 3.
Aforementioned pharmaceutical compositions can be prepared from by the method for preparing pill or tablet well known in the art, preferred version is: crude drug is made medicated powder according to a conventional method respectively, cross 100 mesh sieves, take by weighing in proportion, stirring and evenly mixing, every 100g add refined honey 30g and 10g water, general ball, the heavy 10g of every ball, drying, namely.
The specific embodiment
For the present invention is described better, the present invention partly describes content of the present invention in detail by embodiment, but the embodiment part can not be interpreted as the restriction of spirit of the present invention.
Embodiment 1,
A kind of pharmaceutical composition for the treatment of cerebral infarction, it is got than feedstock production by following weight:
Radix Angelicae Sinensis 35, Flos Chrysanthemi 30, Flos Carthami 25, Radix Puerariae 20, Herba Menthae 18, Semen Persicae 18, the Radix Paeoniae Alba 16, Cornu Cervi 12, Rhizoma Cibotii 12, Radix Salviae Miltiorrhizae 10, the Radix Astragali 10, Ramulus Cinnamomi 8, Rhizoma Gastrodiae 8, Radix Achyranthis Bidentatae 6, Fructus Lycii 6, Cortex Cinnamomi 3, Radix Polygalae 3.
Crude drug is made medicated powder according to a conventional method respectively, cross 100 mesh sieves, take by weighing in proportion, stirring and evenly mixing, every 100g add refined honey 30g and 10g water, general ball, and drying, namely.
Embodiment 2
Medicine of the present invention is to the influence because of the rat brain artery ligation:
Laboratory animal: male SD rat, body weight 280-300g, totally 90;
Medicine: medicine group of the present invention; Control drug group, control drug are nimodipine tablet, Zhengzhou Rui Kang pharmacy, and the 20mg/ sheet is configured to 1ml/mg; The normal saline group.Every group of 30 rats.
Application dosage: medicine group of the present invention: 1g/kg/d; The control drug group, 20mg/kg/d; Normal saline group: the normal saline of same volume.
Experimental technique: rat is implemented cerebral arteries ligation operation, postoperative 20min oral administration according to the Tamura method.
Experimental result: normal rat use medicine of the present invention after 30 minutes cerebral blood flow obviously increase, 60 minutes cerebral blood flows still keep higher level behind the medicine, prolongation in time later on, increasing degree is by ashamed reduction, blood pressure is not had influence, and the normal saline group does not have effect, and the control drug group has certain effect, but it is not obvious
After taking medicine three days, detect the level (table 1) of neural factor NGF in glutamic acid, SOD and the brain of respectively organizing in the laboratory animal cerebral tissue:
Table 1
Conclusion: compare with the normal saline group, medicine group glutamic acid of the present invention obviously reduces, and the SOD level obviously raises, and neural factor NGF improves P＜0.01 greatly in the brain; Compare with the control drug group, medicine group glutamic acid of the present invention reduces relatively, and the SOD level raises, and neural factor NGF improves in the brain, and P＜0.05 possesses significant statistical significance.
Embodiment 3
Clinical trial
The clinical observation on the therapeutic effect experiment of traditional Chinese medicine composition for treating patients with cerebral apoplexy of the present invention
One, the physical data of experimental subject: adopt Chinese medicine composition of the present invention to treat 53 routine patients altogether, male 31 examples wherein, women 22 examples; The oldest person 73 years old, the age reckling has only 2 years old.
Usage and dosage: adopt the prepared medicament of the embodiment of the invention, its usage and consumption are as follows: the each 2-3 grain of pill, every day 3 times, a course for the treatment of two Mondays, take 3-5 the course for the treatment of continuously.
The therapeutic evaluation standard:
Cure: physical signs such as the interior neural factor NGF of glutamic acid, SOD and brain recover normal, and diet is normal, weight increase, and action is normal, and sign is improved fully, and the patient does not have any bad sensation, and mental status is good.
Effectively: physical signs such as the interior neural factor NGF of glutamic acid, SOD and brain change to some extent, and part index number is normal, and diet is normal, weight increase, and pronunciation and action are normal substantially, and the sign major part makes moderate progress, and mental status takes a turn for the better.
Invalid: physical signs such as the interior neural factor NGF of glutamic acid, SOD and brain obviously do not change, and it is not obvious that sign changes, and diet and body weight slightly increase, and lethargy is depressed.
In the 39 routine cases of accepting for medical treatment, through treatment in 2-3 month, wherein cure 25 examples, produce effects 12 examples, invalid 2 examples, total effective rate reaches 95%.The result shows that Chinese medicine composition of the present invention has extremely significant curative effect to the treatment apoplexy.
Above-mentioned each Chinese medicine that the present invention adopts is made compatibility mutually, can bring into play its collaborative effect of curing the disease, having drug effect between each composition of used raw material of Chinese medicine is interweaved and mutually promotes and coordinate usefulness, through clinical verification, constipation there is good therapeutic effect, in the medical practice in nearly ten years of the applicant, the case number of curing is numerous, all obtain good effect, and with low cost, alleviate patient's burden.The Chinese medicine composition of the application's treatment constipation is with low cost, evident in efficacy, has broad application prospects.
Model case:
1, Lee so-and-so, man, 5 years old.During inspection, find that it influences the brain blood supply wretched insufficiency, cause the brain function ateliosis, cerebral blood flow is on the low side, the motor system hypoevolutism, just can stand up about eight or nine months, just slowly can sit after 13 months, can creep during two October, can hold up in the time of two years old the station and hold up away, two upper limb muscular tension can not have, and two muscle tension of lower extremities are high slightly, two ankle shake contraction positives.Took Chinese medicine composition of the present invention 3 months, symptom disappears substantially, and it is normal that biochemical indicator recovers, and can ownly freely play, and walks substantially freely, and body weight and diet heighten, with normal child of the same age and indistinction.
2, model so-and-so, woman, 46 years old.No matter ictal right side limbs followed dysphonia 10 days, cerebral infarction, right limb activity ability, hypertension, brain blood supply wretched insufficiency, and endocrine confusion.After taking medicine, cerebral infarction partly disappears, and it is normal that biochemical indicator recovers, and walks substantially freely, and body weight and diet heighten, and the right limb activity ability is normal.
Claims (2)
1. pharmaceutical composition that is used for cerebral infarction is characterized in that described pharmaceutical composition is got than feedstock production by following weight:
Radix Angelicae Sinensis 35, Flos Chrysanthemi 30, Flos Carthami 25, Radix Puerariae 20, Herba Menthae 18, Semen Persicae 18, the Radix Paeoniae Alba 16, Cornu Cervi 12, Rhizoma Cibotii 12, Radix Salviae Miltiorrhizae 10, the Radix Astragali 10, Ramulus Cinnamomi 8, Rhizoma Gastrodiae 8, Radix Achyranthis Bidentatae 6, Fructus Lycii 6, Cortex Cinnamomi 3, Radix Polygalae 3.
2. pharmaceutical composition as claimed in claim 1 is characterized in that, described pharmaceutical composition is prepared from by the following method: crude drug is made medicated powder according to a conventional method respectively, cross 100 mesh sieves, take by weighing in proportion, stirring and evenly mixing, every 100g add refined honey 30g and 10g water, general ball, drying, namely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103555785A CN102389533B (en) | 2011-11-11 | 2011-11-11 | Medicinal composition for treating cerebral apoplexy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103555785A CN102389533B (en) | 2011-11-11 | 2011-11-11 | Medicinal composition for treating cerebral apoplexy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102389533A CN102389533A (en) | 2012-03-28 |
| CN102389533B true CN102389533B (en) | 2013-08-28 |
Family
ID=45856998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103555785A Active CN102389533B (en) | 2011-11-11 | 2011-11-11 | Medicinal composition for treating cerebral apoplexy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102389533B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634291A (en) * | 2004-10-26 | 2005-07-06 | 辽宁省血栓病中西医结合医疗中心 | Chinese traditional medicine with thrombus eliminating and brain caring function and preparation method thereof |
| CN101766685B (en) * | 2008-12-31 | 2012-11-21 | 成都中医药大学 | Pharmaceutical composite for treating cerebral stroke, preparation method and application thereof |
| CN102106999B (en) * | 2011-02-11 | 2016-05-11 | 冯学功 | A kind of compound Chinese medicinal preparation for the treatment of dysphagia after apoplexy and preparation method thereof |
-
2011
- 2011-11-11 CN CN2011103555785A patent/CN102389533B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102389533A (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614440B (en) | Multi-herb antibacterial liquid | |
| CN101810803B (en) | Chinese medicinal composition for treating hematuria and use of prepared medicine | |
| CN101711833A (en) | Medicine composition for treating fatigue syndrome of sub-healthy people and hypodynamia and inferior immunologic function of patient with acquired immune deficiency syndrome and preparation method thereof | |
| CN103356877A (en) | Traditional Chinese medicine composition for treating orthopedic diseases | |
| CN103393966B (en) | A kind of Chinese medicine composition for the treatment of menoxenia | |
| CN102188583A (en) | Traditional Chinese medicine for treating infertility | |
| CN114377062B (en) | Traditional Chinese medicine composition for treating liver and kidney deficiency type bone arthralgia, preparation and application | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN101152354A (en) | Traditional Chinese medicine for treating acute dacryocystitis | |
| CN102114195B (en) | Anti-drug capsule prepared from pure traditional Chinese medicines | |
| CN101433586B (en) | Medicament for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN101130052A (en) | Traditional Chinese medicine for treating postpartum arthralgia | |
| CN102389533B (en) | Medicinal composition for treating cerebral apoplexy and preparation method thereof | |
| CN103550702A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis | |
| CN102614324A (en) | Chinese medicinal synthetic preparation for assisting western medicines in treating phlebophlogosis | |
| CN100534496C (en) | Chinese medicine for treating ischemic necrosis of femoral head | |
| CN105311140A (en) | Pharmaceutical composition for treating cervical spondylosis and preparation method thereof | |
| CN101549057A (en) | Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same | |
| CN102114211B (en) | Chinese herbal medicine for treating hepatopathy | |
| CN1055242C (en) | Chinese medicine for curing aseptic necrosis of head of femur | |
| CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy | |
| CN102335352B (en) | Traditional Chinese medicine composition for treating ischemic cerebral apoplexy | |
| CN102727615A (en) | Traditional Chinese medicine for treating deep venous thrombosis and method for preparing traditional Chinese medicine | |
| CN102225132A (en) | Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof | |
| CN1064535C (en) | Medicinal powder for treatment of chronic ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU HUAXINYUAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG XIANJUN Effective date: 20141229 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276000 LINYI, SHANDONG PROVINCE TO: 226500 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141229 Address after: 226500 Jiangsu city of Rugao Province Town North Street Flower Market Road No. 20 Patentee after: Jiangsu Xinyuan Pharmaceutical Co., Ltd. Address before: Yizhou road 276000 Shandong province Lanshan District Linyi City District No. 49 south medicine neural medical ward two people's Hospital of Linyi City Patentee before: Wang Xianjun |